Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Sarah Cannon Research Institute and AstraZeneca Partner

Published: Monday, July 08, 2013
Last Updated: Monday, July 08, 2013
Bookmark and Share
Institute and company announce personalized medicine partnership and enhanced strategic clinical development collaboration.

Sarah Cannon Research Institute (SCRI) and AstraZeneca (AZ) announced a collaboration in the field of personalized medicine to support development of new AstraZeneca oncology compounds. Specifically, the parties will work together on molecular profiling to classify tissue based upon genetic profiles for the purpose of treating cancers and predicting response to therapy.

“Through our research, we know how vital and impactful individualized treatment options are for patients battling this complex disease,” said Dee Anna Smith, chief executive officer of SCRI. “By partnering with AstraZeneca, we are expanding opportunities to accelerate drug development and deliver more targeted therapies to patients who urgently need them.”

Under the agreement, SCRI will work with AstraZeneca to identify potential patients for clinical trials and help explore biomarkers that predict response to specific treatments. In addition, SCRI’s enhanced relationship with AstraZeneca will provide clinical program development leadership, medical expertise and oversight, and operational contract research organization (CRO) trial management for early phase clinical development of multiple oncology compounds.

“Building upon this unique collaboration with SCRI allows us to continue honing our capabilities to deliver high quality research in a timely and cost-effective manner,” said Vice President of Early Clinical Development for AstraZeneca, Professor Andrew Hughes. “Through this cutting-edge program design, we can rapidly and effectively implement clinical trials with greater access to a network of cancer patients for enrollment.”

AstraZeneca is one of the initial participants in SCRI’s molecular profiling program, which is part of Sarah Cannon’s broader personalized medicine initiative across the United States and United Kingdom. SCRI and AstraZeneca originally entered into an agreement to develop novel oncology compounds in 2010.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More Than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
The Rise of 3D Cell Culture and in vitro Model Systems for Drug Discovery and Toxicology
An overview of the current technology and the challenges and benefits over 2D cell culture models plus some of the latest advances relating to human health research.
World’s Largest Coral Gene Database
‘Genetic toolkit’ will help shed light on which species survive climate change.
A Boost for Regenerative Medicine
Growing tissues and organs in the lab for transplantation into patients could become easier after scientists discovered an effective way to produce three-dimensional networks of blood vessels, vital for tissue survival yet a current stumbling block in regenerative medicine.
Breast Cancer Drug Hope
A drug for breast cancer that is more effective than existing medicines may be a step closer thanks to new research.
Untangling Disease-Related Protein Misfolding
Work advances understanding of genetic forms of thrombosis, emphysema, cirrhosis of the liver, neurodegenerative diseases and inflammation, among others.
Early Genetic Changes in Premalignant Colorectal Tissue Identified
Findings point to drivers of early cancer development, targets for cancer prevention therapies.
Harnessing Nature’s Vast Array of Venoms for Drug Discovery
Scripps scientists have developed a method for rapidly identifying venoms.
Scientists Find Evidence That Cancer Can Arise Changes
Researchers at Rockefeller University have found a mutation that affects the proteins that package DNA without changing the DNA itself can cause a rare form of cancer.
Developing a More Precise Seasonal Flu Vaccine
During the 2014-15 flu season, the poor match between the virus used to make the world’s vaccine stocks and the circulating seasonal virus yielded a vaccine that was less than 20 percent effective.
A Peachy Defense System for Seeds
ETH chemists are developing a new coating method to protect seeds from being eaten by insects. In doing so, they have drawn inspiration from the humble peach and a few of its peers.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!